Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | PSEN1 | P49768 | 4/20 | 0.38 |
| ▸ | PSEN2 | P49810 | 4/20 | 0.38 |
| ▸ | APH1B | Q8WW43 | 4/20 | 0.38 |
| ▸ | NCSTN | Q92542 | 4/20 | 0.38 |
| ▸ | APH1A | Q96BI3 | 4/20 | 0.38 |
| ▸ | PSENEN | Q9NZ42 | 4/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | CA3 | P07451 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL953919 | 0.83 | PDE2A (0.50) | CES2CES1ADRA2CADRA2AADRA2B | |
| SCHEMBL23729241 | 0.83 | ADRA2C (0.41) | ADRA2CADRA2AADRA2BADRA1AADRA1B | |
| SCHEMBL14640345 | 0.82 | PSEN1 (0.40) | CES2CES1PSEN1PSEN2APH1B | |
| SCHEMBL24222112 | 0.82 | PSEN1 (0.40) | CES2CES1PSEN1PSEN2APH1B | |
| SCHEMBL28843379 | 0.82 | CES2 (0.44) | CES2CES1ADRA2CADRA2AADRA2B | |
| SCHEMBL3199954 | 0.81 | PSEN1 (0.49) | CES2CES1ADRA2CADRA2AADRA2B | |
| SCHEMBL31074203 | 0.81 | PSEN1 (0.49) | CES2CES1ADRA2CADRA2AADRA2B | |
| SCHEMBL30446775 | 0.81 | PSEN1 (0.49) | CES2CES1ADRA2CADRA2AADRA2B | |
| SCHEMBL16957740 | 0.81 | CES2 (0.36) | CES2CES1PSEN1PSEN2APH1B | |
| SCHEMBL22241272 | 0.81 | CES2 (0.36) | CES2CES1PSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7399775-B2 | β-amyloid protein production/secretion inhibitor | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-07-15 | — | — | US | disclosed |
| US-7399775-B2 | β-amyloid protein production/secretion inhibitor | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-07-15 | — | — | US | disclosed |
| US-7399775-B2 | β-amyloid protein production/secretion inhibitor | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-07-15 | — | — | US | disclosed |
| US-20070293495-A1 | BETA-AMYLOID PROTEIN PRODUCTION/SECRETION INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-12-20 | — | — | US | disclosed |
| US-20070293495-A1 | BETA-AMYLOID PROTEIN PRODUCTION/SECRETION INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-12-20 | — | — | US | disclosed |
| US-20070293495-A1 | BETA-AMYLOID PROTEIN PRODUCTION/SECRETION INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-12-20 | — | — | US | disclosed |
| US-20050234109-A1 | to treat Alzheimer's disease,Down syndrome and the other diseases associated with amyloid deposition; thiomethane, sulfinylmethane or sulfonylmethane compounds; 5-Chloro-4-[(4-chlorophenylsulfonyl)-(2,5-difluorophenyl)methyl]-2-(4'-hydroxypiperidin-1'-yl)pyridine | DAIICHI PHARMACEUTICAL CO. LTD. (JP) | 2005-10-20 | — | — | US | disclosed |
| EP-1466898-A1 | BETA-AMYLOID PROTEIN PRODUCTION/SECRETION INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234109-A1 | to treat Alzheimer's disease,Down syndrome and the other diseases associated with amyloid deposition; thiomethane, sulfinylmethane or sulfonylmethane compounds; 5-Chloro-4-[(4-chlorophenylsulfonyl)-(2,5-difluorophenyl)methyl]-2-(4'-hydroxypiperidin-1'-yl)pyridine | APP, PSEN1, PSEN2 | CES2 709/4885CES1 600/4885ADRA2C 570/4885 |
| US-20070293495-A1 | BETA-AMYLOID PROTEIN PRODUCTION/SECRETION INHIBITORS | APP, IAPP, BACE1 | CES2 1338/4885CES1 636/4885ADRA2C 1350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.